Ozempic vs Mounjaro vs Retatrutide — Four Generations of GLP Research

Science doesn’t invent. It discovers and then asks what happens when it extends what it finds.

Liraglutide identified GLP-1 and achieved 8% average weight loss. This was the proof. The question that followed wasn’t “how do we modify this?” It was “what if we also activated GLP-2?” Semaglutide arrived in 2021 and hit 15%.

By 2023, the question evolved again. What if we also activated GIP?

Generations of compounds

29%

Retatrutide (emerging data)

Tirzepatide targeted GLP-1 and GIP and achieved 19.5%. Retatrutide—still in trials—targets GLP-1, GIP, and GCG. Early data shows 29%.

The pattern is consistent across all four generations. Each is not a new invention. Each is the next question asked of biology. And each time the question becomes more specific, the answer becomes more complete.

Each GLP-class generation is not a new invention. It is the next question asked of biology.

This scientific trajectory matters because it reveals something about how medicine moves forward. It doesn’t move through radical innovation. It moves through patient questions and deeper investigation. The body had already built these signals. Science simply learned to read them in parallel instead of sequence.

Ready to see the product?

Science Explained